Mission Therapeutics doses first Parkinson’s patient in Phase 1b
Mission Therapeutics has dosed the first patient in its Phase 1b MTX325-101 study for Parkinson’s disease at Royal Liverpool University Hospital in the United Kingdom. The trial is planned to enrol 36 participants with mild to moderate idiopathic Parkinson’s across the UK, Europe and Australia and i
<p>Mission Therapeutics has dosed the first patient in its Phase 1b MTX325-101 study for Parkinson’s disease at Royal Liverpool University Hospital in the United Kingdom. The trial is planned to enrol 36 participants with mild to moderate idiopathic Parkinson’s across the UK, Europe and Australia and i</p>